Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Context Therapeutics Inc.

Ticker
CNTX
Sector
Industry
Report date
November 11, 2026
Valye AI Score

97

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight clinical progress, corporate milestones, and financial results for Context Therapeutics.

Recent developments:
  • Context Therapeutics was added to the Russell 2000 and Russell 3000 indices in July 2026, reflecting increased market recognition [N1].
  • The company reported encouraging early responses in the Phase 1 trial of CTIM-76 in June 2026 [N2].
  • In Q1 2026, Context recorded an $8 million loss while advancing bispecific antibody programs for cancer treatment [N3].
  • Context Therapeutics gained FDA Fast Track status for CTIM-76 in ovarian cancer in April 2026 [N4].
  • The company planned to report interim Phase 1a data for CTIM-76 in June 2026 and disclosed a widened net loss for fiscal year 2025 [N5].
  • Context announced inducement grants under Nasdaq Listing Rule 5635(c)(4) in January 2026 [N6].
  • Multiple analyst firms initiated or maintained buy and overweight recommendations for Context Therapeutics during late 2025 and early 2026 [N7][N8].
Overview

Context Therapeutics Inc. focuses on developing innovative T cell engaging bispecific antibodies for solid tumors. Its pipeline includes CTIM-76 targeting Claudin 6, CT-95 targeting Mesothelin, and CT-202 targeting Nectin-4. CTIM-76 and CT-95 are in Phase 1 clinical trials, with CT-202 preparing for first-in-human trials. The company retains worldwide rights to its key assets and aims to rapidly advance clinical programs while expanding its pipeline and exploring strategic partnerships. Financially, the company reported a net loss in Q3 2026 and holds cash reserves sufficient for near-term operations but acknowledges risks related to capital needs and Nasdaq listing compliance.

Executive summary

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies targeting solid tumors, with three main candidates: CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3). The company has active Phase 1 clinical trials for CTIM-76 and CT-95, with CT-202 planned to enter clinical trials in late 2026. Financially, as of September 30, 2026, the company reported a net loss of $7.6 million and held $34.4 million in cash and equivalents, with liquidity ratios indicating strong short-term financial health but disclosed substantial doubt about its ability to continue as a going concern beyond one year without additional capital. The company faces Nasdaq listing compliance challenges due to share price but has multiple analyst buy recommendations and recent positive clinical and corporate developments [S1][S2][N1][N2][N3][N4][N5][N7][N8]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for CNTX

Bull case model:

The company’s differentiated T cell engager candidates targeting validated solid tumor antigens with novel mechanisms, such as avidity enhancement and pH-dependent binding, could address significant unmet medical needs across multiple cancer types. Early clinical data for CTIM-76 shows encouraging responses, and FDA Fast Track designation supports accelerated development. The broad potential patient populations and strategic rights ownership provide opportunities for pipeline expansion and partnerships.

Bear case model:

Context Therapeutics faces substantial risks including its clinical-stage status with no approved products, ongoing net losses, and dependence on raising additional capital to fund operations. The company disclosed substantial doubt about its ability to continue as a going concern beyond one year without new funding. Nasdaq listing compliance challenges due to share price could impact liquidity and investor confidence. Clinical and regulatory risks inherent in drug development remain significant.

Moat:

Context Therapeutics’ moat is based on its proprietary T cell engaging bispecific antibody technology targeting solid tumor antigens with selectivity and novel mechanisms such as pH-dependent binding to reduce off-target effects. The company’s clinical-stage pipeline includes differentiated candidates with potential broader patient populations due to targeting tumors with varying antigen expression levels. Exclusive worldwide rights to key patents and know-how, combined with ongoing clinical development and strategic flexibility, contribute to its competitive positioning in the oncology biopharmaceutical sector.

Risks overview
Risks summary
The most significant risk is the company’s disclosed substantial doubt about its ability to continue as a going concern without additional capital, compounded by Nasdaq listing compliance challenges and inherent clinical development uncertainties.
Risks details:

• Capital and Liquidity Risk: The company has disclosed substantial doubt about its ability to continue as a going concern beyond one year from the 10-Q filing date due to limited cash runway and the need for additional capital to fund clinical trials and operations [S2].
• Nasdaq Listing Compliance Risk: Context Therapeutics received a notice of non-compliance with Nasdaq’s minimum bid price requirement in July 2026 and must regain compliance by January 25, 2027, or face potential delisting, which could adversely affect financing and stock liquidity [S2].
• Clinical Development Risk: As a clinical-stage biopharmaceutical company, the success of its product candidates depends on clinical trial outcomes, regulatory approvals, and the ability to demonstrate safety and efficacy, all of which carry inherent uncertainties [S1].
• Operational and Strategic Risk: Failure to raise capital may require the company to curtail operations, delay or discontinue development programs, seek less favorable partnerships, or consider liquidation, which could result in loss of shareholder value [S2].

FINAL FORECAST FOR CNTX

Final take one line
Context Therapeutics is a clinical-stage biopharmaceutical company with a well-documented pipeline of T cell engaging bispecific antibodies targeting solid tumors, facing capital and Nasdaq listing risks amid ongoing clinical development.
Final take 12 to 24 month view

Business trends: Advancement of clinical-stage T cell engager programs CTIM-76, CT-95, and CT-202 targeting solid tumors with differentiated mechanisms and expanding pipeline opportunities.
Execution milestones: Reporting of Phase 1a interim data for CTIM-76 and CT-95, initiation of CT-202 Phase 1 trial, and strategic evaluations including partnerships and commercialization rights.
Key risks: Substantial doubt about going concern due to capital needs, Nasdaq listing compliance challenges, and inherent clinical and regulatory uncertainties in drug development.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

97
LLM visibility overview
LLM Visibility known facts
  • Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies (TCE bsAb) for solid tumors [S1].
  • The company’s pipeline includes three main product candidates: CTIM-76 (Claudin 6 x CD3 TCE), CT-95 (Mesothelin x CD3 TCE), and CT-202 (Nectin-4 x CD3 TCE) [S1].
  • CTIM-76 targets CLDN6, a protein expressed in multiple solid tumors but low or absent in healthy adult tissues; IND-enabling studies are complete, and a Phase 1 dose escalation and expansion trial started dosing the first patient in January 2025 [S1].
  • CTIM-76 Phase 1a interim data was planned for June 2026 [S1][N5].
  • CT-95 targets MSLN, overexpressed in approximately 30% of cancers; the company acquired CT-95 assets in July 2024 and dosed the first patient in its Phase 1 trial in April 2025 [S1].
  • CT-202 targets Nectin-4, a clinically validated target with associated adverse events; CT-202 is designed to be preferentially active in the tumor microenvironment due to pH-dependent binding [S1].
  • The company submitted an application to the Australian Bellberry Human Research Ethics Committee in March 2026 to initiate a first-in-human trial for CT-202, with first patient dosing planned for Q3 2026 [S1].
  • Context retains full worldwide development and commercialization rights for CTIM-76, CT-95, and certain CT-202 patents [S1].
  • The company’s strategy includes advancing clinical programs rapidly through Phase 1 proof of concept, expanding the pipeline, and evaluating strategic opportunities including partnerships and out-licensing [S1].
  • Clinical trials for CTIM-76 enroll patients with CLDN6-positive ovarian, endometrial, and testicular cancers; testicular cancer enrollment does not require prospective screening due to high CLDN6 expression [S1].
  • CT-95 Phase 1 trial enrolls patients with solid tumors likely to express MSLN, including ovarian, pancreatic, and mesothelioma cancers; MSLN expression is not required for enrollment [S1].
  • CT-202 is designed to reduce dermatologic side effects common with Nectin-4 targeting therapies by pH-dependent binding and avidity enhancement [S1].
  • The company reported a net loss of $7.6 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.08 per share [S2].
  • As of September 30, 2026, Context Therapeutics had $34.4 million in cash and cash equivalents, current assets of $36.3 million, current liabilities of $5.5 million, resulting in a current ratio of 6.59 and a cash ratio of 6.26 [S2].
  • The company disclosed substantial doubt about its ability to continue as a going concern beyond one year from the 10-Q issuance date due to cash runway limitations and the need for additional capital [S2].
  • Context Therapeutics’ common stock is listed on Nasdaq but was notified in July 2026 of non-compliance with the minimum bid price requirement; the company has until January 25, 2027, to regain compliance [S2].
  • The company has received multiple buy and overweight recommendations from various analysts and trading firms in late 2025 and early 2026 [N7][N8].
  • Recent news highlights include addition to Russell 2000 and 3000 indices, encouraging early Phase 1 trial responses for CTIM-76, FDA Fast Track status for CTIM-76 in ovarian cancer, and advancing bispecific antibody programs [N1][N2][N3][N4].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-23 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-07-07 | www.nasdaq.com | Context Gains Addition To Russell 2000 And Russell 3000 Indices | https://www.nasdaq.com/articles/context-gains-addition-russell-2000-and-russell-3000-indices
  • N2 | 2026-06-15 | www.nasdaq.com | Context Therapeutics Reports Encouraging Early Responses In Phase 1 Trial Of CTIM-76 | https://www.nasdaq.com/articles/context-therapeutics-reports-encouraging-early-responses-phase-1-trial-ctim-76
  • N3 | 2026-05-07 | www.nasdaq.com | Context Records $8 Mln Loss In Q1; Advances Bispecific Antibody Programs For Cancer Treatment | https://www.nasdaq.com/articles/context-records-8-mln-loss-q1-advances-bispecific-antibody-programs-cancer-treatment
  • N4 | 2026-04-02 | www.nasdaq.com | Context Therapeutics Gains FDA Fast Track Status For CTIM-76 In Ovarian Cancer | https://www.nasdaq.com/articles/context-therapeutics-gains-fda-fast-track-status-ctim-76-ovarian-cancer
  • N5 | 2026-03-24 | www.nasdaq.com | Context Plans To Report CTIM-76 Interim Phase 1a Data In June 2026; FY25 Net Loss Widens | https://www.nasdaq.com/articles/context-plans-report-ctim-76-interim-phase-1a-data-june-2026-fy25-net-loss-widens
  • N6 | 2026-01-16 | www.globenewswire.com | Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | https://www.globenewswire.com/news-release/2026/01/16/3220552/0/en/Context-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
  • N7 | 2025-12-22 | www.nasdaq.com | Jones Trading Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation | https://www.nasdaq.com/articles/jones-trading-initiates-coverage-context-therapeutics-cntx-buy-recommendation
  • N8 | 2025-11-06 | www.nasdaq.com | D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-context-therapeutics-cntx-buy-recommendation-0
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine